Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from BioLife Solutions ( (BLFS) ) is now available.
On March 2, 2026 BioLife Solutions issued an investor presentation outlining its current positioning as a leading provider of biopreservation media and cell processing tools for cell-based therapies, highlighting its mission to protect cell integrity and enable development and delivery of advanced treatments. The February 2026 presentation detailed 2025 pro forma results, including $96 million in revenue, 29% organic growth, a 26% adjusted EBITDA margin and a 65% gross margin, with revenue largely driven by consumable biopreservation media specified in more than 950 global clinical trials and numerous commercially approved therapies.
The materials also emphasized BioLife’s 28-year innovation track, from early biopreservation work to its role in supporting approved cell-based therapies such as Yescarta, and chronicled a recent strategic pivot away from lower-margin storage, services and freezer operations toward higher-growth cell processing consumables. Management presented the divestitures of cold chain storage and freezer assets and the acquisitions of PanTHERA and a stake in Pluristyx as having improved growth durability, profitability and net cash, reinforcing BioLife’s positioning as an industry leader in tools that underpin ex vivo cell and gene therapy workflows.
The most recent analyst rating on (BLFS) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on BioLife Solutions stock, see the BLFS Stock Forecast page.
Spark’s Take on BLFS Stock
According to Spark, TipRanks’ AI Analyst, BLFS is a Neutral.
The score is driven primarily by improving financial momentum (strong growth, solid margins, low leverage, and positive free cash flow) and a favorable earnings outlook pointing to potential first-time GAAP profitability in 2026. These positives are tempered by weak valuation signals tied to currently negative earnings and only mixed technical conditions, plus margin and concentration risks highlighted on the earnings call.
To see Spark’s full report on BLFS stock, click here.
More about BioLife Solutions
BioLife Solutions, Inc. is a leading provider of biopreservation media and cell processing tools for cell-based therapies, supplying products such as CryoStor, HypoThermosol, CellSeal vials and hPL solutions. The company focuses on supporting ex vivo cell and gene therapies globally, with a 2025 revenue mix heavily concentrated in high-margin, consumable biopreservation media and tools used in hundreds of clinical trials and multiple approved commercial therapies.
BioLife has steadily evolved from its R&D origins and biopreservation focus into an integrated tools and services provider, with a strategic refocus in 2024-2025 on cell processing consumables following divestitures of storage, services and freezer businesses. This repositioning, under CEO Rod de Greef, has shifted the portfolio toward higher growth and profitability, supported by targeted acquisitions such as PanTHERA and an investment in Pluristyx, and underpins its claim to industry leadership in solutions for cell-based therapies.
Average Trading Volume: 354,002
Technical Sentiment Signal: Buy
Current Market Cap: $1.17B
For detailed information about BLFS stock, go to TipRanks’ Stock Analysis page.